Literature DB >> 18425370

Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women.

Yongmei Li1, Qinjun Wei, Fang Cao, Xin Cao.   

Abstract

The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. In this study, we detected the RASSF1A promoter methylation by methylated-specific PCR and investigated RASSF1A gene expression by semi-quantitative RT-PCR and immunohistochemical staining in 36 cases of breast cancer and their adjacent normal tissues in Chinese women. The promoter methylation of the RASSF1A gene was found to be a frequent event in the breast cancers (61.1%). RASSF1A methylation was not found in the matched adjacent normal tissues. The loss frequency of RASSF1A mRNA was 33.3% and that of the RASSF1A protein was 44.4% in breast cancers. RASSF1A mRNA and protein were all expressed in adjacent normal tissues. The mRNA and protein expression level of RASSF1A was significantly lower in breast cancer than in adjacent normal tissue. However, the promoter methylation of the RASSF1A gene in breast cancers were not correlated with clinical parameters, such as ages, histological types, TNM stages and lymph node metastases. Thus, the promoter methylation of RASSF1A was one reason for the low level of RASSF1A mRNA and protein expression and was a frequent event in primary sporadic breast tumorigenesis in Chinese women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425370

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation.

Authors:  Micah G Donovan; Spencer N Wren; Mikia Cenker; Ornella I Selmin; Donato F Romagnolo
Journal:  Br J Pharmacol       Date:  2020-01-26       Impact factor: 8.739

2.  Methylation status and protein expression of RASSF1A in breast cancer patients.

Authors:  Hoda A Hagrass; Heba F Pasha; Mohamed A Shaheen; Eman H Abdel Bary; Rasha Kassem
Journal:  Mol Biol Rep       Date:  2013-11-20       Impact factor: 2.316

3.  Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma.

Authors:  Lang Hu; Gang Chen; Hongping Yu; Xiaoqiang Qiu
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

Review 4.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

5.  DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide.

Authors:  Berna Demircan; Burcu Yucel; James A Radosevich
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

6.  Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.

Authors:  Giorgio Malpeli; Eliana Amato; Mario Dandrea; Caterina Fumagalli; Valentina Debattisti; Letizia Boninsegna; Giuseppe Pelosi; Massimo Falconi; Aldo Scarpa
Journal:  BMC Cancer       Date:  2011-08-12       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.